 |
|
|
| |
Efficacy and Safety of Ombitasvir/Paritaprevir/r and Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
With a History of Bleeding Disorders: Results From Phase 3 Trials
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Giustino Parruti 1, Guilherme Macedo2, Axel Baumgarten3, Frederik Nevens4, Jordan J Feld5, Christophe Hézode6, Lois Larsen7, Nancy S Shulman7, Regis A Vilchez7*, Fernando Tatsch7, Heiner Wedemeyer8
1Ospedale Civile Spirito Santo, Pescara, Italy; 2Centro Hospitalar de São João, Porto, Portugal; 3Medical Center for Infecti ous Diseases, Berlin, Germany; 4University Hospitals KU, Leuven, Belgium; 5Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada;
6Henri Mondor University Hospital, AP-HP, Université Paris-Est, Créteil, France; 7Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, United States; 8Medizinische Hochschule Hannover, Hannover, Germany
|
| |
|
|
|
|
|
